Kornimate/medical-research-clean huggingface dataset:
ablation of prostate tissue utilizing sterile water vapor in patients with intermediate risk localized prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this research study is to collect information on a new treatment of prostate tissue participants with intermediate risk prostate cancer using a medical device called the poseidon system. the poseidon system is intended to ablate prostate tissue in areas of the prostate where cancer has been identified. the medical device delivers thermal energy in the form of water vapor to the prostate tissue through the urethra. previous research has shown successful prostate tissue ablation. additional research may help show successful ablation of the prostate tissue where cancer is located.


Eligibility criteria:
inclusion criteria: * 45-80 years old * biopsy confirmed unilateral, adenocarcinoma of the prostate * minimum of 12 biopsy cores obtained ≥4 weeks and ≤12 months before treatment. targeted fusion biopsy is preferred if there is a mri pi-rads ≥3 lesion. it is preferred a standard 12 sector biopsy is mapped. mri required if biopsy was completed \>6 months prior to treatment date to confirm no mri progression of disease that would be considered exclusionary. * ≤4 of 6 standard sector biopsy cores positive for prostate cancer (unilateral); positive core(s) from a targeted lesion count as one positive core. * gleason score of 7 (3+4) / international society of urological pathologists (isup) gleason grade group (ggg) 2 * clinical stage less than or equal to t2b n0 m0 * psa (prostate specific antigen) less than or equal to 15ng/ml * prostate size 20-80cc exclusion criteria: * malignant tumors identified by extraprostatic extension, sphincter involvement/lesion abutment seminal vesicle invasion or lymph node invasion or metastasis * narrow peripheral zone * mri identified pi-rads ≥4 lesion contralateral to the side that has biopsy confirmed adenocarcinoma * prior definitive treatment of prostate cancer
chronic obstructive pulmonary disease: ct features of severe exacerbation

Conditions: COPD Exacerbation

Summary: to describe computed tomography (ct) features associated with severe exacerbations of chronic obstructive pulmonary disease (copd).

the natural course of copd is associated with episodes of exacerbation which are clinically defined as acute events characterized by a worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and which leads to a change in medication. moreover, these episodes can be classified into mild, moderate, or severe exacerbations, following patient's need for medical environment. while the cause of about one-third of severe exacerbation episodes cannot be identified, two-thirds are associated with certain conditions such as respiratory tract infections (viral or bacterial), air pollution, as well as pulmonary embolism (pe), pulmonary edema, cardiac arrhythmia, pneumothorax, or pleural effusion. as copd exacerbations are associated with increased morbidity and mortality, as well as with increased healthcare costs, their prevention and treatment are two major objectives in copd management with subsequent requirement for appropriate assessment tools. as imaging tool, chest radiography is limited to the detection of pneumonia and pleural abnormalities, and only leads to change in managements in a marginal proportion of patients. however, while computed tomography (ct) scans allows detecting more chest abnormalities, the knowledge of ct features at the time of exacerbation is a pre-requisite for determining possible role of ct in routine work-up of exacerbation. nevertheless these features remain widely unknown, previous studies having focused on the prevalence of pe. the aim of our study was therefore to describe these features by comparing ct scans performed at severe exacerbation with control scans.

Eligibility criteria:
inclusion criteria: * severe exacerbation episode of copd, requiring hospital admission exclusion criteria: * no exclusion criteria

Keywords: chest computed tomography
proximal tibial open wedge osteotomy. a clinical prospective, randomized rsa-trial.

Conditions: Osteoarthritis, Knee

Summary: in the treatment of osteoarthritis of the medial compartment of the knee, open wedge high tibial osteotomy is a good choice of treatment for the young and active patient. however it leaves an open gap which has to be filled with a bone substitute and requires stable fixation. hitherto the golden standard has been autograft taken from iliac crest but there are donorsite related problems and limited amount available. recently injectable and resorbable calciumphosphate-cements have been introduced and used with promising results in fractures of the distal radius, calcaneus and lateral tibial condyle. these new cements seem to be a good alternative to other bone substitutes providing high initial strength that might promote early mobilisation; it resorbs and promotes osteoconduction securing safe healing. the aim of the present study is to evaluate whether there is any difference in clinical outcome, correction, stability and healing in open-wedge osteotomies with three different bone substitutes: autograft from iliac crest and the injectable calciumphosphate-cement calcibon and as control a group with an empty gap. osteosynthesis is performed with the dynafix® system (ebi) the investigation is performed as a randomised prospective clinical trial including 45 patients with a planned 2 years follow-up period. clinical outcome is evaluated with: hospital of special surgery score, koos, sf 12 and lysholm score. routine standing x-rays is performed. stability is assessed with roentgen stereophotogrammetric analysis (rsa) that provides the opportunity of exact 3-dimensional measuring of eventual loss of correction. this combined with urine and serum bone-healing markers gives a very precise picture of the healing in the bone-gap. to asses the cartilage of the knee mri is performed and biochemical markers fore collagen type ii degradation are measured.


Eligibility criteria:
inclusion criteria: * osteoarthritis of medial compartment of the knee, ahlbäck gr. 1-2 * candidate for proximal tibial medial open-wedge osteotomy * signed informed consent exclusion criteria: * prednisolone treatment. * nsaid treatment. * bmi \> or = 35. * previous surgery in lateral knee compartment. * secondary arthrosis following fracture(s) of the tibial condyle(s). * lack of informed consent.

Keywords: osteoarthritis, knee osteotomy healing roentgen stereometric analysis
a study of prexasertib (ly2606368) in combination with ralimetinib in participants with advanced or metastatic cancer

Conditions: Advanced Cancer; Metastatic Cancer; Colorectal Cancer; Non-small Cell Lung Cancer

Summary: the main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.


Eligibility criteria:
inclusion criteria: * advanced or metastatic cancer. * able to swallow tablets. * for part b, you will need to have colon cancer or non-small cell lung (nsclc) cancer with kras and/or braf mutations. * discontinued all previous treatments for cancer and recovered from the acute effects from the therapy. exclusion criteria: * active infection (fungal, viral, or bacterial). * active cancer in your brain or spinal cord. * acute or chronic leukemia. * serious heart condition. * disease that requires immunosuppressant therapy. * diagnosis of inflammatory bowel disease. * major small bowel resection that interferes with your body's ability to absorb the oral medicine. * participated in other clinical trials investigating prexasertib or ralimetinib. * pregnant or breastfeeding. * other pre-existing conditions or medical history which your doctor will explain to you.
kinesiotaping and post-dry needling soreness

Conditions: Mechanical Neck Pain

Summary: application of trigger point dry needling can induce post-dry needling soreness. this is not a negative experience, but sometimes some patients want to reduce it as much as possible. different therapeutic strategies targeting to decrease post-dry needling soreness need to be investigated. since kinesiotaping has been advocated for decreasing tone in the muscle tissues, it would be a potential intervention for this objective.


Eligibility criteria:
inclusion criteria: - generalized neck-shoulder pain with symptoms provoked by neck postures, neck movement, or palpation of the cervical musculature exclusion criteria: * any contraindication to dry needling * whiplash injury; * previous cervical surgery; * cervical radiculopathy or myelopathy; * diagnosis of fibromyalgia syndrome; * having undergone any therapy intervention for the neck are in the previous 6 months; * fear to needles; * less than 18 or greater than 65 years of age.
evaluation of the effect of a spatial localization training program on auditory comprehension

Conditions: Hearing Loss, Cochlear

Summary: hearing comprehension under complex listening conditions is considered to be the central complaint of everyday life for patients with cochlear implants. localization is one of the cues for listening comprehension. however, only few studies have investigated the effect of spatial localization training on listening comprehension performance in noise. none of these studies correspond to the desire to purpose training by speech therapists while using affordable equipment. the main objective of this study is to evaluate the effect of a spatial localization training protocol in cochlear bi-implanted subjects with post-lingual deafness on their ability to understand in noise. 2 groups of 10 subjects each will be recruited: a patient group and a control group. the patient group will undergo 8 sessions of spatial localization rehabilitation lasting an average of 45 minutes each. after this programme, the pre-test and post- test results obtained will be compared.


Eligibility criteria:
inclusion criteria: * post-lingual deafness * implanted bilaterally for at least 1 year * score ≥ 70 at lafon scale * score ≥ 70 at mbaa scale * score ≥ 5/9 at cap scale * good command of the french language * accepts to participate in the study exclusion criteria: * do not realize speech reeducation (spatial localisation and speech perception) during the study * no change in setting of cochlear implants
study of dupilumab and immune responses in adults with atopic dermatitis (ad)

Conditions: Atopic Dermatitis

Summary: this was a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous dupilumab.


Eligibility criteria:
key inclusion criteria: 1. male or female adults ages 18 to 64 years with chronic ad (according to the american academy of dermatology consensus criteria, \[eichenfeld 2004\])that has been present for at least 3 years before the screening visit 2. participants with documented recent history (within 6 months before the screening visit) of inadequate response to a sufficient course of outpatient treatment with topical ad medication(s), or for whom topical ad therapies are otherwise inadvisable (e.g., because of side effects or safety risks). 3. eczema area and severity index (easi) score ≥16 at the screening visit and the baseline visit 4. investigator's global assessment (iga) score ≥3 (on the 0-4 iga scale) at the screening and baseline visits 5. ≥10% body surface area (bsa) of ad involvement at the screening and baseline visits key exclusion criteria: 1. prior treatment with dupilumab (regn668/ sar231893) 2. patients needing \>10 mg of daily prednisone (including equivalent doses of other steroids) or high dose systemic corticosteroids (≥2 mg/kg) for 14 days or longer during the 16 week treatment period of the study 3. history of guillain-barre syndrome 4. history of severe allergic reaction to either vaccine or to vaccine components including alum, thimerosal, phenol 5. patients with a severe reaction to natural rubber latex products (some packaging components of the vaccines contain rubber latex and may cause a reaction in susceptible individuals) 6. treatment with biologics within 4 months of baseline visit 7. chronic or acute infection requiring treatment with antibiotics, antivirals, antiparasitics, antifungals within 4 weeks before screening visit or superficial skin infections within 1 week of screening visit the information listed above is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial and not all inclusion/ exclusion criteria are listed.
avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment

Conditions: Leiomyosarcoma Metastatic

Summary: a phase 2 trial of avelumab plus gemcitabine in advanced leiomyosarcoma as a second line treatment


Eligibility criteria:
inclusion criteria: 1. unresectable, advanced or metastatic histologically confirmed leiomyosarcoma 2. progression during or after first-line doxorubicin-based chemotherapy (relapse within 6 months of completion of adjuvant/neoadjuvant chemotherapy containing doxorubicin-based regimen could be considered as first-line therapy.) 3. ecog ps 0-2 4. at least one measurable lesion according to recist v1.1 5. adequate organ function 6. life expectancy \>= 3 months 7. negative serum or urine pregnancy test at screening for women of childbearing potential exclusion criteria: 1. prior treatment history of anti-pd-1/pd-l1 or anti-ctla4 treatment 2. receipt of 2 or more prior systemic treatments for advanced leiomyosarcoma 3. active or untreated brain metastases or spinal cord compression 4. prior treatment with gemcitabine 5. history of major surgery within 4 weeks prior to enrollment 6. chemotherapy or radiotherapy within 3 weeks prior to the study drug commencement 7. previous malignant disease other than leiomyosarcoma within the last 5 years with the exception of basal or squamous cell carcinoma of skin or carcinoma in situ (bladder, cervical, colorectal, breast) 8. pregnant or lactating women 9. hiv, hbv, or hcv infection 10. severe hypersensitivity or anaphylaxis to monoclonal antibody, or uncontrolled bronchial asthma 11. current use of immunosuppressive agent (exclusion : less than prednisone 10 mg/day or equivalent) 12. active autoimmune disease 13. clinically significant cardiovascular disease 14. clinically significant interstitial pneumonitis or pulmonary fibrosis 15. vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
buteyko method for children with asthma

Conditions: Asthma; Child; Breathing Exercises

Summary: this study has the aim to assess the effectiveness of the buteyko method as an adjunct therapy in the treatment of children with asthma.

children from 7 to 12 years old with asthma diagnose will be included. children in the intervention group will perform 6 sessions (twice a week) of treatment with the buteyko method. children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma. the investigators will assess quality of life by the paqlq (paediatric asthma quality of life questionnaire), pulmonary function (spirometry) and the six-minute walk test. vital signs, pulmonary auscultation and oxygen peripheral saturation will also be assessed during the tests. in addition, information will be collected on the numbers of hospitalizations, occurence of absence in school due to exacerbation of the disease, asthma symptoms and beta2-agonists usage .

Eligibility criteria:
inclusion criteria: * children from 7 up to 12 years old with asthma diagnose; * regular inhaled corticosteroids with no change in dose in the preceding 4 weeks; * children cannot present: other respiratory disease (such as cystic fibrosis, bronchiectasis, tuberculosis), retinal detachment, hypertensive crisis, congenital heart defect, pulmonary edema, history of lobectomy or lung segmentectomy, respiratory infections 15 days prior to the evaluations. exclusion criteria: * children that are not able to perform some of the necessary procedures; * give up participating in the research and present acute symptoms of respiratory tract during the assessments.

Keywords: asthma physical therapy specialty breathing exercises child clinical trail
the effect of fluids consumption on balance and gait function in old adults

Conditions: Aging; Dehydration

Summary: experimental design overview the proposed project is a prospective experimental rct study design. independent old adults(age 65 years old and older) who do not suffer from balance problems willing to participate in the study will be tested before and after water consumption to explore whether there are differences in balance control as a result of dehydration.

experimental design overview the proposed project is a prospective experimental study design. independent old adults(age 65 years old and older) who do not suffer from balance problems willing to participate in the study will be tested with well-established measuring techniques of balance control before and 2 hours after mineral water consumption (1 liter) in the movement and rehabilitation laboratory at bgu. an automated algorithm will be used to extract standardized stabilogram-diffusion parameters from each of the cop data sets collected during quiet standing. these parameters include diffusion coefficients, critical displacement, critical time and scaling exponents for both lateral and anterior-posterior sway directions (collins \& de luca, 1993). for each of the conditions (before and 1 hour after the use of ritalin) in three task conditions single task; dual task (concentrating and identifying specific music); and just listening to a relaxing music. participants will be required to stand on the platform 10 times for 30 s. for each trial, they will be instructed to sway as little as possible.

Eligibility criteria:
inclusion criteria: * age 65 years old and older * independent elderly adults * do not suffer from balance problems * mini-mental score 24 and above exclusion criteria: * old adults who suffer from neurological disease or stroke * old adults who suffer from psychiatric state * old adults who suffer from orthopedic condition (1/2 a year after a fracture in the lower limb) * old adults who suffer from heart conditions * old adults who suffer from blindness

Keywords: ageing balance control falls dehydration
effect of postoperative ferric carboxymaltose

Conditions: Postoperative Anemia; Knee Osteoarthritis; Total Knee Arthroplasty

Summary: the primary purpose of this study is to evaluate the safety and efficacy of postoperative intravenous ferric carboxymaltose in patients with anemia undergoing simultaneous bilateral total knee replacement in terms of quality of life (qol) and objective measures (hemoglobin and iron parameters).

both preoperative and postoperative anaemia are common in patients undergoing total knee arthroplasty. allogeneic rbc (red blood cell) transfusion and anaemia are related with higher postoperative mortality and morbidity. it is important to have a strategy of patient blood management. hb(hemoglobin) level of 10 g/dl will be used as a cut-off value for our study. in postoperative period in total knee arthroplasty for osteoarthritis, consented patients with postoperative anemia will be administered ferinject® or placebo (normal saline) based on the results of randomization. study group: ferinject® administration as iv drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg(milligram) single administration) for body weight ≥50 kg (kilogram) or 6 minutes (for 500mg(milligram) single administration) for body weight \< 50kg( kilogram) . control group: placebo in the form of normal saline administration as same time period as equivalent ferinject® administration. iv drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200ml(milliliter) as infusion or 20ml(milliliter) as bolus injection) for body weight ≥50 kg ( kilogram) or 6 minutes (100ml normal as infusion or 10ml(milliliter) as bolus injection) for body weight \<50 kg (kilogram).

Eligibility criteria:
inclusion criteria: * \> 18 years of age and signed written informed consent * patients scheduled to undergo major orthopaedic surgery (hip or knee arthroplasty or back surgery) * hb \< 10.0 g/dl after operation * ferritin \< 100 μg/l or 100-300 with transferrin saturation \< 20% exclusion criteria: * suspicion of iron overload (ferritin \>300 μg/l or/and transferrin saturation\>50%) * active severe infection/inflammation (defined as serum c reactive protein \> 20 mg/l) or diagnosed malignancy * folate-and/or vitamin b12 deficiency (according to local lab reference range) * known history of hepatitis b/c or hiv-positive * liver values 3 times higher than normal * immunosuppressive or myelosuppressive therapy * a concurrent medical condition(s) that, in the view of the investigator, would prevent compliance or participation or jeopardize the health of the patients. * pregnancy or lactation * transfusion within 1 month prior to study inclusion, erythropoietin treatment with in the last 4 weeks, any iron treatment within 4 weeks prior to the inclusion in the trail * participation in any other therapeutic trial within the previous month * history of thromboembolic events in the family or the patient * severe peripheral, coronary or carotid artery disease * bodyweight \< 50 kg * patients not able to understand the german language
imaging of prostate and breast cancer bone metastases using magnetic resonance imaging and nuclear medicine techniques

Conditions: Bone Metastases

Summary: prostate and breast cancer continues to be the most common cancer among men and women, respectively. the exact assessment of the cancer spread with detection of possible bone metastasis is crucial for treatment decision. in the current study 50 patients with prostate cancer and 50 patients with breast cancer at high risk for bone metastases or with know metastatic disease will be studied with multiple imaging modalities. patients will be recruited from the department of oncology, turku university hospital. planar bone scintigraphy (bs), single photon emission computed tomography combined with low-dose computed tomography (spect/ct), 18f-fluoride positron emission tomography computed tomography (pet/ct) and magnetic resonance imaging (mri) will be performed to all patients. the primary objective is to determine the diagnostic accuracy of the four imaging modalities. the secondary goal is to calculate the sensitivities and specificities of the four imaging modalities on a patient-to-patient and lesion-to-lesion basis. based on the results of this study an optimal imaging protocol for detection of prostate and breast cancer bone metastasis will be developed and validated.


Eligibility criteria:
inclusion criteria: * age: 40 to 80 years * language spoken: finnish or swedish * performance status: karnofsky score 70 or better or who performance status 2 or better * diagnosis: histologically confirmed prostate or breast cancer * mental status: patients must be able to understand the meaning of the study * informed consent: the patient must sign the appropriate ethics committee (ec) approved informed consent documents in the presence of the designated staff * strong suspicion of first bone metastatic disease (already diagnosed metastases in other organs, elevated tumor markers, destruction of bone in plain x-ray or otherwise specified reasons * adjuvant chemo- or endocrine therapy is allowed exclusion criteria: * ongoing treatment for metastatic disease * contraindications for mri (cardiac pacemaker, intracranial clips etc.) * infections: patient must not have an uncontrolled serious infection * claustrophobia